GH1 and neoplasm: A recently published study, compared Octreotide and Pasireotide (Octreotide 100 μg s.c. thrice daily, followed by Pasireotide 200, 400 or 600 μg s.c. twice daily for 28 days each) for the effect on GH, tumour growth, and glucose metabolism.